MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.96
+0.35
+1.88%
Closed 16:54 03/01 EST
OPEN
18.96
PREV CLOSE
18.61
HIGH
19.30
LOW
18.57
VOLUME
427.79K
TURNOVER
--
52 WEEK HIGH
23.84
52 WEEK LOW
10.15
MARKET CAP
882.54M
P/E (TTM)
-7.8041
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Radius Health (RDUS) Receives a Hold from Leerink Partners
SmarterAnalyst · 23h ago
Postmenopausal Osteoporosis Market Size, Share, Trends, Analysis and Forecast 2018-2023
Mar 01, 2021 (Market Insight Reports) -- The postmenopausal osteoporosis market is expected to grow significantly during the forecast period (2018-2023)....
Market Insight Reports · 1d ago
DJ Radius Health Price Target Raised to $23.00/Share From $20.00 by SVB Leerink
Dow Jones · 1d ago
DJ Radius Health Is Maintained at Market Perform by SVB Leerink
Dow Jones · 1d ago
--Analyst Actions: SVB Leerink Adjusts Price Target on Radius Health to $23 From $20, Maintains Market Perform Rating
MT Newswires · 1d ago
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
Zacks.com · 3d ago
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
Zacks.com · 3d ago
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
Zacks.com · 3d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDUS. Analyze the recent business situations of Radius Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDUS stock price target is 22.71 with a high estimate of 30.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 223
Institutional Holdings: 60.97M
% Owned: 130.98%
Shares Outstanding: 46.55M
TypeInstitutionsShares
Increased
40
4.59M
New
32
-1.22M
Decreased
47
2.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Independent Director
Owen Hughes
President/Chief Executive Officer/Director
G. Kelly Martin
Chief Financial Officer/Chief Accounting Officer/Treasurer
James Chopas
Senior Vice President
Chhaya Shah
Other
Bruce Mitlak
Director
Sean Murphy
Director
Machelle Sanders
Director
Andrew Von Eschenbach
  • Dividends
  • Splits
  • Insider Activity
No Data
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.